MGC Pharmaceuticals has formally changed its name to Argent BioPharma after the move was approved by shareholders last month.
The name change has been processed by the Australian Securities and Investments Commission (ASIC) and will take effect on the ASX from the start of trading on Wednesday (April 3).
The firm’s ASX code will migrate to RGT and its website address is now www.argentbiopharma.com.
Shareholdings are unaffected and no new share certificates will be issued.
Managing Director and CEO of Argent BioPharma Roby Zomer said: “As Argent BioPharma emerges from MGC Pharma, it is well positioned in the new era in biopharmaceuticals, committed to providing accessible and impactful healthcare solutions on a global scale.
“This rebranding signifies our commitment to innovation and advancement in the biopharmaceutical landscape.
“We are excited to leverage our expertise in polypharmacology and nanotechnology to pioneer ground-breaking treatments, addressing unmet medical needs and driving positive change in global healthcare.”
